Abstract
A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine. He achieved a complete remission (CR) after two cycles of therapy, and he remained in remission during 1 year of treatment. He developed recurrent AML after discontinuation of decitabine. He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine.
| Original language | English |
|---|---|
| Pages (from-to) | 543-545 |
| Number of pages | 3 |
| Journal | American journal of hematology |
| Volume | 81 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2006 |
Keywords
- Acute myeloid leukemia
- Decitabine
- Myelodysplastic syndromes